BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

BRILIQUE (ticagrelor) 90mg twice daily  in combination with  acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment


Brilique Clinical Studies

BRILIQUE (ticagrelor) demonstrated acute and long-term CV protection across two large studies: PLATO and PEGASUS-TIMI 54 respectively.4,15

The PLATO study compared BRILIQUE (ticagrelor) (180-mg loading dose, 90mg twice daily thereafter) and clopidogrel (300-mg to 600-mg loading dose, 75 mg daily thereafter) for the prevention of thrombotic CV events (CV death, MI, or stroke) in 18,624 patients admitted to hospital with an ACS with or without ST-segment elevation. Patients were treated for at least 6 months and up to 12 months.4

BRILIQUE (ticagrelor) – the only oral antiplatelet with evidence demonstrating a statistically and clinically significant reduction in CV mortality at 12 months compared to clopidogrel in patients with ACS.4,16

The PEGASUS-TIMI 54 study compared BRILIQUE (ticagrelor) (90 mg twice daily or 60 mg twice daily) vs. placebo, each given with low-dose aspirin, for the prevention of thrombotic CV events (CV death, MI, or stroke) in 21,162 patients ≥50 years of age with a history of MI (1 to 3 years prior to randomisation) and at high risk* of another atherothrombotic event.15

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)

CPRD adherence data

Study results

Medically managed ACS patients are at highest risk of subsequent events34 and show the lowest persistence with treatment34

  • Medically managed MI patients are at greater risk of a subsequent CV event vs invasively managed patients,18,35 and tend to be older and undertreated, with a greater comorbidity burden18
  • To promote adherence in these patients, it is essential to initiate medication before discharge,18 provide education about their condition and treatment, and complete regular monitoring36

Analysis of patient persistencea on BRILIQUE (ticagrelor) 90 mg over 15 months in ACS patients in primary care. Data from the CPRD database. The x-axis begins at month 1 as only primary care prescriptions are included (assuming 1-month hospital supply on discharge)34

 Persistence to treatment is defined as time from initiation to discontinuation of therapy in primary care (first ticagrelor prescription date, to last prescription date plus duration supplied on last prescription).34
ACS, acute coronary syndrome; CABG, Coronary Artery Bypass Grafting; CPRD, Clinical Practice Research Datalink; PCI, Percutaneous coronary intervention.

CPRD ticagrelor outcomes study design34

Analysis of prescription data from English GP practices within CPRD that are linked to Hospital Episode Statistics data, including patients with a first primary care BRILIQUE prescription issued between December 2010 and March 2015. A 1-month prescription of BRILIQUE from the hospital at discharge was assumed.

Inclusion criteria

  • ≥12 months of patient history in the database before the first prescription
  • ACS event in the 3 months prior to inclusion
  • Alive and registered with the practice 11 months after inclusion

Exclusion criteria

  • Primary care prescription for clopidogrel or prasugrel between the ACS event and inclusion